作者
Matthew J Gorman, Nita Patel, Mimi Guebre-Xabier, Alex Zhu, Caroline Atyeo, Krista M Pullen, Carolin Loos, Yenny Goez-Gazi, Ricardo Carrion Jr, Jing-Hui Tian, Dansu Yaun, Kathryn Bowman, Bin Zhou, Sonia Maciejewski, Marisa E McGrath, James Logue, Matthew B Frieman, David Montefiori, Colin Mann, Sharon Schendel, Fatima Amanat, Florian Krammer, Erica Ollmann Saphire, Douglas Lauffenburger, Ann M Greene, Alyse D Portnoff, Michael J Massare, Larry Ellingsworth, Gregory Glenn, Gale Smith, Galit Alter
发表日期
2021/2/5
期刊
bioRxiv
出版商
Cold Spring Harbor Laboratory Preprints
简介
Recently approved vaccines have already shown remarkable protection in limiting SARS-CoV-2 associated disease. However, immunologic mechanism (s) of protection, as well as how boosting alters immunity to wildtype and newly emerging strains, remain incompletely understood. Here we deeply profiled the humoral immune response in a cohort of non-human primates immunized with a stable recombinant full-length SARS-CoV-2 spike (S) glycoprotein (NVX-CoV2373) at two dose levels, administered as a single or two-dose regimen with a saponin-based adjuvant Matrix-M™. While antigen dose had some effect on Fc-effector profiles, both antigen dose and boosting significantly altered overall titers, neutralization and Fc-effector profiles, driving unique vaccine-induced antibody fingerprints. Combined differences in antibody effector functions and neutralization were strongly associated with distinct levels of …
学术搜索中的文章
MJ Gorman, N Patel, M Guebre-Xabier, A Zhu, C Atyeo… - bioRxiv, 2021